Cadonilimab: First Approval

Cadonilimab (^®), a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumours, including cervical Cancer, lung Cancer, gastric/gastroesophageal junction Cancer, oesophageal squamous cell Cancer, liver Cancer and nasopharyngeal Cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical Cancer (r/mCC) who have progressed on or after platinum-based chemotherapy. This article summarizes the milestones in the development of cadonilimab leading to this first approval for the treatment of patients with r/mCC.